Etiology of venous thrombosis: The need for small original studies

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 10, 2012, Pages 2189-2190

  Rosendaal, F R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C;

ANTICOAGULATION; GENETIC ASSOCIATION; HEREDITY; LUNG EMBOLISM; NOTE; OBESITY; ORAL CONTRACEPTION; PATHOGENESIS; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SMOKING; THROMBOPHILIA; VEIN THROMBOSIS;

ABO BLOOD-GROUP SYSTEM; FACTOR V; FEMALE; HUMANS; MALE; POINT MUTATION; SMOKING; VENOUS THROMBOEMBOLISM;

EID: 84866879017     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04881.x     Document Type: Note

References (13)

1. Virchow R. Phlogose und Thrombose im Gefäßsystem; Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt: Staatsdruckerei, 1856.
2. Jick H, Slone D, Westerholm B, Inman WHW, Vessey MP, Shapiro S, Lewis GP, Worcester J. Venous thromboembolic disease and ABO blood type. Lancet 1969; i: 539-42.
3. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995; 345: 152-5.
4. Morelli VM, De Visser MC, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 2005; 3: 183-5.
5. le Cessie S, Debeij J, Rosendaal FR, Cannegieter SC, Vandenbroucke JP. Quantification of bias in direct effects estimates due to different types of measurement error in the mediator. Epidemiology 2012; 23: 551-60.
6. Dahlbäck B. The discovery of activated protein C resistance. J Thromb Haemost 2003; 1: 3-9.
7. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
8. Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
9. Jordan WM. Pulmonary embolism. Lancet 1961; ii: 1146-7.
10. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
11. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
12. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med 2008; 5: e67.
13. Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75: 524-5.